Skin Cancer

The AJMC® Skin Cancer compendium is a comprehensive resource for clinical news and expert insights about melanoma and other skin cancers.

Latest News

Advancing health equity can be achieved through community engagement | image credit: Andrii - stock.adobe.com
Community Engagement, Culturally Tailored Care as a Gateway to Advancing Health Equity

October 16th 2024

Many talks at the Association of Cancer Care Centers (ACCC) 41st National Oncology Conference advocated for the adoption of culturally relevant care, the leveraging of community partnerships, and community engagement to build better trust with patients and improve outcomes.

Biofrontera's red-light LED has been approved for the treatment of actinic keratosis | image credit: marog-pixcells - stock.adobe.com
FDA-Approved Red-Light LED Lamp Released for Patients With Actinic Keratosis

June 28th 2024

skin cancer | Image Credit: uffoow-stock.adobe.com
Certain Melanoma Subtype May Be More Sensitive to NK, T Cells

June 28th 2024

Medicaid coverage | image credit: nelzajamal - stock.adobe.com
Further Medicaid Expansion Would Benefit Patients With Melanoma, Study Finds

June 20th 2024

Pregnancy-associated melanoma is a rare occurence that impacts 1 in 2200 pregnancies | image credit: Alik Mulikov - stock.adobe.com
Management of Melanoma During Pregnancy Explored at ASCO 2024

June 15th 2024

Dr. Jason Luke leads a panel discussing immunotherapy advances in Cutaneous and Basal Cell Carcinoma

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Georgina V. Long, MBBS, PhD
July 14th 2022

KEYNOTE-716: First Data on DMFS Show Additional Pembrolizumab Benefit in Patients With Melanoma

Maggie L. Shaw
New date from the KEYNOTE-716 trial show distant metastasis-free survival benefit from pembrolizumab use in melanoma.
Image of DNA under a microscope
July 12th 2022

Genetic Patterns, Targeted Therapy Resistance Link in Melanoma Explored in New Study

Jared Kaltwasser
The analysis could help investigators better understand why a subset of patients with advanced melanoma develops resistance or does not respond to targeted therapy.
Image of a dermatologist examining a patient's skin
July 7th 2022

High-risk Mohs Surgery Outcomes Superior to Historical Data for cSCC, Study Shows

Jared Kaltwasser
This new report suggests patients with high-risk cutaneous squamous cell carcinoma (cSCC) have improved odds when they undergo Mohs micrographic surgery.
Image of possible skin cancer
June 24th 2022

Adjuvant Pembrolizumab Shows Favorable Health-Related Quality-of-Life Results in Resected Melanoma

Rose McNulty
An interim analysis of the KEYNOTE-716 trial of adjuvant pembrolizumab supports its use in the adjuvant setting for patients with resected melanoma.
Dabrafenib Plus Trametinib Approved as First Tumor-Agnostic Therapy for BRAF V600E–Mutated Solid Tumors
June 22nd 2022

Dabrafenib Plus Trametinib Approved as First Tumor-Agnostic Therapy for BRAF V600E–Mutated Solid Tumors

Allison Inserro
The combination is the first and only therapy to be approved with a tumor-agnostic indication in both children and adults with solid tumors that have a BRAF V600E mutation, Novartis said late Wednesday.
Omid Hamid, MD
June 15th 2022

Dr Omid Hamid on Choosing Targeted Therapy in Advanced Melanoma

AJMC Staff
Omid A. Hamid, MD, chief of Translational Research and Immunotherapy, director, Melanoma Therapeutics, The Angeles Clinic and Research Institute, spoke with The American Journal of Managed Care® (AJMC®) about evaluating therapy options for patients with advanced melanoma.
Early Study of Brain-Permeable BRAF Inhibitor Shows Positive Results
June 11th 2022

Early Study of Brain-Permeable BRAF Inhibitor Shows Positive Results

AJMC Staff
Brain metastasis from melanoma is particularly deadly and options are limited due to the difficulty of breaching the brain-blood barrier.
operating room
June 3rd 2022

Older Patients Receiving Mohs Surgery Typically Have Facial Tumors, Are High-Functioning

Jared Kaltwasser
Investigators also found patients in nursing homes tend to have larger tumors and may experience quality-of-life benefits from the procedure.
dna image
June 1st 2022

SLC25A13 Could Be Prognostic, Therapeutic Biomarker in Skin Cutaneous Melanoma

Jared Kaltwasser
The analysis suggests the marker could be used to screen patients for potential immunotherapy.
doctors in hospital
May 28th 2022

Researchers Establish, Validate Prognostic Model for Uveal Melanoma

Jaime Rosenberg
The model consists of 3 metabolism-related genes—carbonic anhydrase 12, acyl-CoA synthetase long-chain family member 3, and synaptojanin 2— that the researchers said could potentially be used as biomarkers and treatment targets in the disease.
Jeffrey Weber, MD, PhD
May 23rd 2022

Dr Jeffrey Weber on the Staging of Melanoma and Choosing Treatment Options

AJMC Staff
Medical oncologist Jeffrey S. Weber, MD, PhD, spoke with The American Journal of Managed Care® (AJMC®) about how treatment options have improved for more advanced melanoma cases and the role that genetic mutations play in choosing therapy.
image of skin cancer
May 22nd 2022

Skin Microenvironment Could Yield New Melanoma Treatment Options, Study Finds

Jared Kaltwasser
The microenvironment of the skin also helps explain why certain ethnicities appear to have a higher risk of melanoma.
injection
May 18th 2022

Real-World Analysis Explores Clinical Activity, Safety of PD-1 Inhibition in Advanced BCC

Rose McNulty
Locally advanced or metastatic basal cell carcinoma can be challenging to treat, but programmed death receptor 1 inhibition may hold potential as a tolerable, effective approach in patients of all ages.
graphic of melanoma
May 15th 2022

Apatinib Prompts Responses in Patients With Recurrent Melanoma

Jared Kaltwasser
The drug yielded partial responses in 2 of 15 patients in this single-arm, phase 2 study.
Image of the word melanoma
May 13th 2022

Melanoma Prevalence, Mortality Mostly Stable Over the Past 30 Years

Jared Kaltwasser
Data from this new study suggest melanoma cases rose at a slower rate in lower-income countries, but the authors say that may be due to differences in case documentation.
Image of a skin cancer exam
May 9th 2022

Study Suggests Awareness Alone Will Not Solve Skin Cancer Overdiagnosis Issue

Jared Kaltwasser
More experienced dermatopathologists were less likely to see overdiagnosis as a significant public health problem, a new survey showed.
Image of researcher examining DNA
May 5th 2022

Investigation Yields Potential New Genetic Biomarker for Anti–PD-1 Success in Melanoma

Jared Kaltwasser
Investigators found 6 genes associated with cancer-associated fibroblasts that appear to correlate with response to anti-PD-1 immunotherapy.
Image of a digital eye
May 2nd 2022

Genetic Advances Could Change Management of Uveal Melanoma

Jared Kaltwasser
Although classic methods of risk stratification still hold value, the authors said genetic analysis holds significant promise.
doctor's coat
April 27th 2022

Australian Study Finds General Practitioners Tend to Adhere to Guidelines When Treating Melanoma

Jared Kaltwasser
The finding is important because evidence suggests it is becoming more common for patients to receive care from a general practitioner for skin cancer, versus a surgeon or dermatologist.
Dr Martin Dietrich Describes Need to Move Quickly With “Aggressive, Unpredictable” Melanoma
April 27th 2022

Dr Martin Dietrich Describes Need to Move Quickly With “Aggressive, Unpredictable” Melanoma

AJMC Staff
Martin Dietrich, MD, PhD, of Florida Cancer Specialists spoke with The American Journal of Managed Care® (AJMC®) on risk factors in melanoma, as well as the need for genomic testing and rapid action for a cancer that can progress very quickly.
cells
April 24th 2022

Soluble Microenvironment Appears to Impact How Melanoma Cells Interact With Immune Cells

Jared Kaltwasser
Inflammatory microenvironments appear to enhance melanoma cells’ ability to control T-cell responses.
Image of broken DNA
April 22nd 2022

DNA Mismatch Repair Proteins May Predict ICI Response in Cutaneous Melanoma

Jared Kaltwasser
Patients with reduced DNA mismatch repair protein expression were more likely to respond to immune checkpoint inhibitors (ICIs), although this study had a small sample size.
Image of clinical research
April 19th 2022

Study Probes Immune Context Differences in BRAF-Mutant, Wild-Type Melanoma

Jared Kaltwasser
Investigators said these differences might help explain why some patients have better outcomes than others with combination immune checkpoint blockades.
Image of a skin cancer screening
April 13th 2022

Primary Care Screening for Skin Cancer Appears to Boost Early Detection

Jared Kaltwasser
It is not yet clear what impact proactive screening might have on health care costs and survival outcomes.
old person
April 8th 2022

Study Identifies Risk Factors for Skin Cancer in Older Adults, Highlights Utility of Screening and Prevention

Rose McNulty
A recent study aimed to fill research gaps regarding skin cancer rates and risk factors in older adults.
blue background indicating technology
April 5th 2022

Researchers Propose Novel Methodology for Computer-Aided Diagnostic System in Melanoma

Rose McNulty
Image of exam for skin cancer
March 28th 2022

40-Year Study Finds Skin Cancer on the Rise in the United States

Jared Kaltwasser
The 5-year survival rate over the time period was just 33.8%, the study found.
An image of liquid biopsy analysis
March 22nd 2022

ctDNA Accurately Detects BRAF Mutations in Advanced Melanoma, Study Finds

Jared Kaltwasser
A new report shows better than 80% concordance between liquid biopsy and tissue biopsy.
DNA strand
March 18th 2022

Review: Treatment of Patients with BRAF V600K-Mutant Melanoma Remains Under-Studied

Jared Kaltwasser
Existing research appears to suggest these patients can be treated similarly to patients with other genetic subtypes of cutaneous melanomas.
Graphic of melanoma
October 21st 2021

Personalized Dendritic Cell Vaccination Safe, but More Research Needed on Efficacy

Rose McNulty
Autologous tumor lysate particle-loaded dendritic cell (TLPLDC) vaccination is well-tolerated in combination with other immunotherapies, but further research is needed to confirm its efficacy.
<12345>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo